Drugs / Adrixetinib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07138196 | Dec 2025 → Oct 2029 expected | chronic graft versus host disease | Qurient Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adrixetinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07138196 ↗ |
| Modality | Small molecule | — CHEMBL5314452 ↗ |
| Route | Oral | “Administered orally” NCT07138196 ↗ |